09:04 AM EDT, 09/24/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve foam 0.3% to treat adults and adolescents aged 12 and older with scalp and body psoriasis.

The FDA has set a Prescription Drug User Fee Act target action date of May 22, 2025, the commercial-stage company said.

The sNDA is backed by positive data from Arcutis' pivotal late-stage trial, a phase 2b study, as well as long-term efficacy and safety data generated from the Zoryve cream development program in plaque psoriasis, the company said.

Price: 9.67, Change: +0.04, Percent Change: +0.42